LAUSR

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 283 mucosal healing rates than the placebo. The remission rates at week 8 were 4.3%, 13.3%, and 12.7% for the placebo, abrilumab 70-mg, and abrilumab 210-mg groups, respectively (P < 0.05 for the 70-mg and 210-mg groups vs. placebo group). These results were similar to those observed in a phase 3 GEMINI I trial of vedolizumab in UC patients. In the present issue of Intestinal Research, Hibi et al. reported the results of another phase 2 study involving abrilumab in Japanese UC patients. Forty-five UC patients were randomized to 21 mg (n = 11), 70 mg (n = 12), or 210 mg (n = 9) of abrilumab, or placebo (n = 13) via subcutaneous injection for 12 weeks. The primary endpoint was clinical remission at week 8 (total Mayo score ≤ 2 points with no individual subscore > 1 point). The double-blind period was followed by a 36-week open-label period, in which all patients received abrilumab 210 mg subcutaneously every 12 weeks, and a 28-week safety follow-up period. Clinical remission at week 8 was 4 out of 31 (12.9%) overall in the abrilumab groups versus 0 out of 13 in the placebo group (abrilumab: 21 mg, 1/10 [10.0%]; 70 mg, 2/12 [16.7%]; 210 mg, 1/9 [11.1%]). In both the double-blind and open-label periods, more patients in the placebo group experienced ≥ 1 adverse event compared to those in the abrilumab groups. In this study, although the results were not statistically significant, abrilumab 70 mg and 210 mg yielded numerically pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2019.00070 Intest Res 2019;17(3):283-284